<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03224312</url>
  </required_header>
  <id_info>
    <org_study_id>CONPASS</org_study_id>
    <nct_id>NCT03224312</nct_id>
  </id_info>
  <brief_title>Chongqing Primary Aldosteronism Study</brief_title>
  <official_title>Chongqing Primary Aldosteronism Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We intends to conduct a series of original clinical research about PA, and establish a large&#xD;
      cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular&#xD;
      events, renal end points etc. We will establish a large sample of blood, urine, adrenal&#xD;
      tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the&#xD;
      mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include the subjects of a series of studies on hypertension conducted by our&#xD;
      team, including essential hypertension, PA subjects, and establish a large sample database&#xD;
      and specimen bank through follow-up and omics analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of patients who develop cardiovascular events</measure>
    <time_frame>1-15 years</time_frame>
    <description>compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the incidence of hypertensive nephropathy between two groups (based on eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of new atrial fibrillation</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of left ventricular hypertrophy</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the variation of carotid intima-media thickness</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subgroup analysis of cardiovascular events</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the cardiovascular and cerebrovascular risk between unilateral PA and idiopathic bilateral adrenal hyperplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life score</measure>
    <time_frame>1-15 years</time_frame>
    <description>Compare the quality of life between unilateral PA and idiopathic bilateral adrenal hyperplasia by the questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk score</measure>
    <time_frame>1-15 years</time_frame>
    <description>To investigate what kind of cardiovascular risk score can better predict cardiovascular risk of PA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Primary Aldosteronism</condition>
  <arm_group>
    <arm_group_label>Primary aldosteronism</arm_group_label>
    <description>screened, confirmed and subtyped according to the guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essential hypertension</arm_group_label>
    <description>screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>Essential hypertension</arm_group_label>
    <arm_group_label>Primary aldosteronism</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma and complete blood cell, adrenals.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hypertensive patients who completed ARR screening and necessary further tests and Voluntary&#xD;
        to be followed up will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. hypertensive patients who completed ARR screening and necessary further tests;&#xD;
&#xD;
          2. Voluntary to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patients with severe cardiac, hepatic or renal dysfunction;&#xD;
&#xD;
          2. suspicious or confirmed other types of secondary hypertension, including Cushing's&#xD;
             syndrome, pheochromocytoma and renal artery stenosis et al.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qifu Li, phD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qifu Li, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>liqifu@yeah.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shumin Yang, phD</last_name>
    <phone>+86 023-89011552</phone>
    <email>443068494@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qifu Li</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qifu Li, PhD</last_name>
      <phone>+86 23 89011552</phone>
      <email>liqifu@yeah.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30.</citation>
    <PMID>28576687</PMID>
  </reference>
  <reference>
    <citation>Monticone S, Burrello J, Tizzani D, Bertello C, Viola A, Buffolo F, Gabetti L, Mengozzi G, Williams TA, Rabbia F, Veglio F, Mulatero P. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J Am Coll Cardiol. 2017 Apr 11;69(14):1811-1820. doi: 10.1016/j.jacc.2017.01.052.</citation>
    <PMID>28385310</PMID>
  </reference>
  <reference>
    <citation>Stowasser M, Gordon RD. Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney. Physiol Rev. 2016 Oct;96(4):1327-84. doi: 10.1152/physrev.00026.2015. Review.</citation>
    <PMID>27535640</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Director of endocrinology</investigator_title>
  </responsible_party>
  <keyword>Primary aldosteronism</keyword>
  <keyword>cardiovascular events</keyword>
  <keyword>cerebrovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperaldosteronism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

